Protein-protein interactions (PPIs) play a key role in cellular signaling, the most common of which is the PDZ structural domain. PDZ domains are abundant protein interaction modules that enable to recognize short amino acid motifs at the C-termini of target proteins. These domains can recognize short C-terminal peptide ligands due to their well-defined binding sites. In addition to this, aberrant PPIs have a non-negligible role and PDZ domains are associated with diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimer's disease, Parkinson's disease, avian influenza, pain and stroke. Thus, the involvement of the PDZ domain in disease pathways provides an important reference for the development of inhibitors capable of targeting PDZ-mediated interactions to inhibit PPI selectively.
BOC Sciences has fully considered the involvement of the PDZ domain in disease pathways, and established the PDZ PPI library by expanding on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Figure 1. Structure of the PDZ domain and mechanism of peptide recognition. (Harris, B. Z.; Wendell, A. 2001)
We provide more than 200 structures of PDZ domains:
Figure 2. The same PDZ domain can recognize two structurally distinct ligands. (Harris, B. Z.; Wendell, A. 2001)
BOC Sciences provides professional, rapid and high-quality services of PDZ PPI Library design at competitive prices for global customers. Personalized and customized services of PDZ PPI Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
BOC Sciences has rich experience in working with global customers in custom library synthesis of compounds and generating small to medium-sized libraries of target compounds. Our knowledge in generating a large number of target molecules in a remarkably shorter time enables quick biological screenings for affinities. With the target properties in mind, we deliver target molecules, by applying our extensive knowledge in drug discovery.